ClinicalTrials.gg
Not yet recruitingNCT07599956SHIELD 1Updated Oct 16, 2026

Artificial Intelligence to Scale Early Rheumatic Heart Disease Detection

An interventional study of AI assisted echocardiography in Rheumatic Heart Disease, sponsored by Children's Hospital Medical Center, Cincinnati. Not yet recruiting at 1 site in Uganda. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Children's Hospital Medical Center, Cincinnati · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati — 7 open to participants now, 7 under way, 2 of them phase 3. Rheumatic Heart Disease · Children's Hospital Medical Center, Cincinnati.

Planned enrollment
9th of 10
62 · median 629
Started
2026
with 3 others
No phase
7 of 13
3 open now
Registered
8th of 13
by date

Among the 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati, this one is the 9th largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2026, is one of 7 with no phase, and was the 8th registered.

Rheumatic Heart Disease

62 studies on the registry are indexed under Rheumatic Heart Disease; 26 are open to participants now.

Browse Rheumatic Heart Disease studies →

Open to participants now

7 of the 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 11 Rheumatic Heart Disease studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Rheumatic Heart Disease by Children's Hospital Medical Center, Cincinnati, or all of them as a file.
02

Study summary

The main goal of this project is to see if RADAR (Rapid AI-assisted Detection and Analysis of Rheumatic heart disease), which is a machine and deep-learning AI model, can help make rheumatic heart disease (RHD) screening easier to expand. Specifically, the project will test whether RADAR can screen as accurately-or more accurately-than current methods, and whether it can be used effectively in different low-resource settings. The aim is to show that RADAR could be adopted and used widely around the world.

03

Conditions studied

  • Rheumatic Heart Disease

Keywords

  • Rheumatic heart disease
  • Artificial Intelligence
  • Deep Learning
  • Machine Learning
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Employed at a participating ADUNU facility
  • Holds a designated role in the ADUNU program as a nurse screener

Exclusion criteria

Exclusion Criteria:

  • None. The pragmatic trial design includes all eligible staff at participating facilities.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Care provider)
Enrollment
62 participants (estimated)

Study arms

  • No intervention
    Standard non-AI echocardiography

    In the Standard non-AI Echocardiography arm, participants will receive the current standard of care under the ADUNU program, which includes a single parasternal long-axis view with black-and-white and color Doppler imaging. Providers have been trained to recognize mitral regurgitation greater than 1.5 or 2 cm, any aortic insufficiency, qualitatively reduced left ventricular systolic function, and pericardial effusion. Detection of any of these findings constitutes a screen positive, prompting referral for a confirmatory echocardiogram.

  • Experimental
    RADAR-AI-assisted echocardiography

    In the RADAR Echocardiography arm, participants will undergo AI-assisted screening according to the well-established RADAR protocol including the same image acquisition protocol but interpreted by the tablet-based software based on two independent AI algorithms 1) RHD positive or negative and 2) mitral regurgitation jet length. Positive findings from either algorithm constitutes a screen positive. Providers may also refer for other concerns.

    Diagnostic Test: AI assisted echocardiography

Interventions

  • Diagnostic testAI assisted echocardiography

    Continue standard of care with AI-assisted echocardiography

06

What researchers measure

Primary outcomes

  1. Accuracy of Provider RHD Screening

    The number of correctly identified (positive or negative) screenings divided by the total number of exams.

    Time frame: 1 year

Secondary outcomes

  1. Interpretation Sensitivity

    The number of correctly identified positive screening exams divided by the sum of correctly identified positive and incorrectly identified negative exams.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Nov 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2026
First posted
May 20, 2026
StartEst.
Nov 2026was Jun 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Nov 2026
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Start date Jun 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07599956
Collaborators
Uganda Heart Institute, Ochsner Health System, Vanderbilt University Medical Center, Children's National Health Center
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Isabella Brigham
Contact
isabella.aspromonte@cchmc.org
513-517-1307
Andrea Beaton
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion